Curaxis Pharmaceutical, once known as Voyager Pharmaceutical, has filed for Chapter 7 bankruptcy.
The Raleigh-based company has fought financial challenges for years as it sought to develop a treatment for Alzheimer’s.
In the bankruptcy filing made July 30, Curaxis listed debts of more than $9.53 million and assets of $14.335.
Earlier this year, Curaxis had been seeking a partner to help advance the candidate Memryte for phase 2B and phase 3 clinical trials.
Curaxis was focused on age-related diseases, pursuing the theory that many diseases of aging may be caused by age-related changes in the function of the hypothalmic-pituitary-gonadal axis, a hormonal feedback loop that affects development, reproduction and aging.
The bankruptcy was filed in the Eastern District of North Carolina.
Curaxis does own a U.S. patent related to prevention and treatment of Alzheimer’s and similar patent in Europe.
It has several patents pending.
